CN101035785A - 具有抗菌活性的新化合物 - Google Patents
具有抗菌活性的新化合物 Download PDFInfo
- Publication number
- CN101035785A CN101035785A CNA200580028501XA CN200580028501A CN101035785A CN 101035785 A CN101035785 A CN 101035785A CN A200580028501X A CNA200580028501X A CN A200580028501XA CN 200580028501 A CN200580028501 A CN 200580028501A CN 101035785 A CN101035785 A CN 101035785A
- Authority
- CN
- China
- Prior art keywords
- methoxy
- nmr
- group
- 300mhz
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004041163.8 | 2004-08-25 | ||
| DE102004041163A DE102004041163A1 (de) | 2004-08-25 | 2004-08-25 | Neue Verbindungen mit antibakterieller Aktivität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101035785A true CN101035785A (zh) | 2007-09-12 |
Family
ID=35431960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200580028501XA Pending CN101035785A (zh) | 2004-08-25 | 2005-08-25 | 具有抗菌活性的新化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070244103A1 (enExample) |
| EP (1) | EP1781650A1 (enExample) |
| JP (1) | JP2008510762A (enExample) |
| KR (1) | KR20070045152A (enExample) |
| CN (1) | CN101035785A (enExample) |
| AU (1) | AU2005276576A1 (enExample) |
| BR (1) | BRPI0514665A2 (enExample) |
| CA (1) | CA2571132A1 (enExample) |
| DE (1) | DE102004041163A1 (enExample) |
| IL (1) | IL179837A0 (enExample) |
| MX (1) | MX2007002097A (enExample) |
| NZ (1) | NZ552036A (enExample) |
| RU (1) | RU2410386C2 (enExample) |
| WO (1) | WO2006021448A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102361863B (zh) * | 2009-01-21 | 2014-12-03 | 巴斯利尔药物股份公司 | 新的二环抗生素 |
| CN104803913A (zh) * | 2014-01-24 | 2015-07-29 | 浙江省化工研究院有限公司 | 一种碳酸苄基喹啉基酯类化合物、其制备方法及应用 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
| CA2580621A1 (en) * | 2004-09-24 | 2006-03-30 | Actelion Pharmaceuticals Ltd | New bicyclic antibiotics |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| BRPI0617376A2 (pt) * | 2005-10-13 | 2011-07-26 | Morphochem Ag | derivados de 5-quinolina tendo uma atividade antibacteriana |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| DE602007009205D1 (de) | 2006-04-06 | 2010-10-28 | Glaxo Group Ltd | Pyrrolochinoxalinonderivate als antibakterielle mittel |
| GB0608263D0 (en) * | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| TW200819457A (en) | 2006-08-30 | 2008-05-01 | Actelion Pharmaceuticals Ltd | Spiro antibiotic derivatives |
| CL2007003693A1 (es) | 2006-12-22 | 2008-06-27 | Actelion Pharmaceuticals Ltd | Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas. |
| CL2008001003A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| WO2008128942A1 (en) * | 2007-04-20 | 2008-10-30 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| SI2182950T1 (en) * | 2007-05-17 | 2018-01-31 | Helperby Therapeutics Limited | Use of 4- (pyrrolidin-1-yl) quinoline compounds for killing clinically latent microorganisms |
| ATE520687T1 (de) * | 2007-06-15 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyranderiva e |
| BRPI0820985A2 (pt) | 2007-12-18 | 2015-06-16 | Actelion Pharmaceuticals Ltd | Composto derivado de 5-aminociclometil-oxazondin-2-ona, medicamento e composição farmacêutica que os contém e uso dos mesmos |
| EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
| MY150596A (en) | 2008-02-01 | 2014-01-30 | Takeda Pharmaceutical | Hsp90 inhibitors |
| BRPI0907892A2 (pt) | 2008-02-20 | 2015-07-28 | Actelion Pharmaceuticals Ltd | Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo |
| CA2720672A1 (en) | 2008-04-15 | 2009-10-22 | Actelion Pharmaceuticals Ltd | Tricyclic antibiotics |
| US8618092B2 (en) | 2008-10-07 | 2013-12-31 | Actelion Pharmaceuticals Ltd. | Tricyclic oxazolidinone antibiotic compounds |
| JP2012505866A (ja) | 2008-10-17 | 2012-03-08 | グラクソ グループ リミテッド | 抗菌剤として使用される三環式窒素化合物 |
| JP5653935B2 (ja) | 2009-01-15 | 2015-01-14 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗菌薬として有用なナフチリジン―２（１ｈ）−オン化合物 |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| EP2513115B1 (en) | 2009-12-18 | 2013-10-09 | Basilea Pharmaceutica AG | Tricyclic antibiotics |
| US9321788B2 (en) | 2011-06-17 | 2016-04-26 | Basilea Pharmaceutica Ag | Tricyclic antibiotics |
| EP2785721A1 (en) | 2011-11-30 | 2014-10-08 | Actelion Pharmaceuticals Ltd. | 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| AR090844A1 (es) * | 2012-04-27 | 2014-12-10 | Actelion Pharmaceuticals Ltd | Proceso para elaborar derivados de naftiridina |
| AR101674A1 (es) | 2014-08-22 | 2017-01-04 | Glaxosmithkline Ip Dev Ltd | Uso de un compuesto tricíclico que contiene nitrógeno |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| MA41168A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
| UY36851A (es) * | 2015-08-16 | 2017-03-31 | Glaxosmithkline Ip Dev Ltd | Compuestos para uso en aplicaciones antibacterianas |
| PL3468975T3 (pl) | 2016-06-08 | 2020-09-07 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Nowe związki przeciwbakteryjne |
| JP6594570B2 (ja) | 2017-03-20 | 2019-10-23 | フォーマ セラピューティクス，インコーポレイテッド | ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物 |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| AU2020350763A1 (en) | 2019-09-19 | 2022-04-07 | Novo Nordisk Health Care Ag | Pyruvate kinase R (PKR) activating compositions |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| RS66978B1 (sr) | 2020-07-02 | 2025-07-31 | Incyte Corp | Triciklična jedinjenja uree kao inhibitori jak2 v617f |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| KR20240144096A (ko) | 2021-11-02 | 2024-10-02 | 플레어 테라퓨틱스 인크. | Pparg 역 효능제 및 그의 용도 |
| KR20240163688A (ko) | 2022-03-17 | 2024-11-19 | 인사이트 코포레이션 | Jak2 v617f 억제제로서의 삼환계 우레아 화합물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2140417C1 (ru) * | 1995-10-17 | 1999-10-27 | Институт физиологически активных веществ РАН | Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения |
| GB0112834D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| JP4445753B2 (ja) * | 2002-01-29 | 2010-04-07 | グラクソ グループ リミテッド | アミノピペリジン誘導体 |
| TW200406413A (en) * | 2002-06-26 | 2004-05-01 | Glaxo Group Ltd | Compounds |
| US7223776B2 (en) * | 2002-10-10 | 2007-05-29 | Morphochem Ag | Compounds with anti-bacterial activity |
| DE10247233A1 (de) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| DE10256405A1 (de) * | 2002-12-02 | 2004-06-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| AR042486A1 (es) * | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
-
2004
- 2004-08-25 DE DE102004041163A patent/DE102004041163A1/de not_active Withdrawn
-
2005
- 2005-08-25 CN CNA200580028501XA patent/CN101035785A/zh active Pending
- 2005-08-25 NZ NZ552036A patent/NZ552036A/en not_active IP Right Cessation
- 2005-08-25 MX MX2007002097A patent/MX2007002097A/es not_active Application Discontinuation
- 2005-08-25 AU AU2005276576A patent/AU2005276576A1/en not_active Abandoned
- 2005-08-25 BR BRPI0514665-8A patent/BRPI0514665A2/pt not_active IP Right Cessation
- 2005-08-25 EP EP05787944A patent/EP1781650A1/en not_active Withdrawn
- 2005-08-25 WO PCT/EP2005/009204 patent/WO2006021448A1/en not_active Ceased
- 2005-08-25 CA CA002571132A patent/CA2571132A1/en not_active Abandoned
- 2005-08-25 KR KR1020067026765A patent/KR20070045152A/ko not_active Ceased
- 2005-08-25 RU RU2007105995/04A patent/RU2410386C2/ru not_active IP Right Cessation
- 2005-08-25 JP JP2007528748A patent/JP2008510762A/ja not_active Withdrawn
- 2005-08-25 US US11/660,894 patent/US20070244103A1/en not_active Abandoned
-
2006
- 2006-12-05 IL IL179837A patent/IL179837A0/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102361863B (zh) * | 2009-01-21 | 2014-12-03 | 巴斯利尔药物股份公司 | 新的二环抗生素 |
| CN104803913A (zh) * | 2014-01-24 | 2015-07-29 | 浙江省化工研究院有限公司 | 一种碳酸苄基喹啉基酯类化合物、其制备方法及应用 |
| CN104803913B (zh) * | 2014-01-24 | 2019-02-12 | 浙江省化工研究院有限公司 | 一种碳酸苄基喹啉基酯类化合物、其制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0514665A2 (pt) | 2009-03-24 |
| JP2008510762A (ja) | 2008-04-10 |
| US20070244103A1 (en) | 2007-10-18 |
| EP1781650A1 (en) | 2007-05-09 |
| DE102004041163A1 (de) | 2006-03-02 |
| AU2005276576A1 (en) | 2006-03-02 |
| RU2410386C2 (ru) | 2011-01-27 |
| RU2007105995A (ru) | 2008-10-10 |
| IL179837A0 (en) | 2007-05-15 |
| WO2006021448A1 (en) | 2006-03-02 |
| KR20070045152A (ko) | 2007-05-02 |
| NZ552036A (en) | 2010-08-27 |
| MX2007002097A (es) | 2007-04-24 |
| CA2571132A1 (en) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101035785A (zh) | 具有抗菌活性的新化合物 | |
| CN1260225C (zh) | 四氢吡啶基或哌啶基杂环衍生物 | |
| CN1033088C (zh) | 新的噻唑基苯并呋喃衍生物的制备方法 | |
| CN1168719C (zh) | 6-苯基吡啶-2-基胺衍生物以及药物组合物和用途 | |
| CN1211384C (zh) | 噻二唑基和噁二唑基苯基噁唑烷酮抗菌剂 | |
| CN1304382C (zh) | 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂 | |
| CN1031570C (zh) | 吡唑并吡啶化合物的制备方法 | |
| CN1046724C (zh) | 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途 | |
| CN1906189A (zh) | 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物 | |
| CN1088917A (zh) | 取代的苄氨基含氮非芳族杂环化合物 | |
| CN1950371A (zh) | 用作组胺h3受体配体的四氢萘啶衍生物 | |
| CN1585749A (zh) | 类大麻苷受体配体 | |
| CN1333753A (zh) | 作为抗病毒剂的喹啉羧酰胺 | |
| CN1795174A (zh) | 新型取代的3－硫吲哚 | |
| CN1761646A (zh) | 大麻素受体配位体 | |
| HK1080073B (zh) | 炔-芳基磷酸二酯酶-4抑制剂 | |
| CN1633416A (zh) | 用作p38抑制剂的烟酰胺衍生物 | |
| CN1678317A (zh) | 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物 | |
| CN1946402A (zh) | 用作ccr3拮抗剂的哌啶衍生物 | |
| CN1787818A (zh) | 趋化因子受体活性的氨基环丁基酰胺调节剂 | |
| CN1347416A (zh) | 取代的3－氰基－[1.7],[1.5]和[1.8]－二氮杂萘酪氨酸激酶抑制剂 | |
| CN101039935A (zh) | 新型哌啶抗生素 | |
| CN1886402A (zh) | 嘧啶－2－胺衍生物及其作为a2b腺苷受体拮抗剂的用途 | |
| CN1035255C (zh) | 杂三环衍生物 | |
| CN1829519A (zh) | 二苯基取代的环烷烃类,含有它们的组合物和应用的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20070912 |